Novartis AG (ADR) (NYSE:NVS)

CAPS Rating: 5 out of 5

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.

Results 1 - 20 of 185 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar OklaBoston (60.07) Submitted: 7/20/2015 4:24:32 PM : Underperform Start Price: $104.58 NVS Score: +0.11

High P/FCF, among other things, leads me to believe this stock's days of deserving 5 Stars are OVER!

Recs

0
Member Avatar solutionorppt (47.33) Submitted: 6/19/2015 2:08:19 PM : Outperform Start Price: $100.38 NVS Score: +3.42

First company to garner FDA approval for a biosimilar, good dividends and management.

Recs

0
Member Avatar cmrk3 (54.26) Submitted: 3/21/2015 10:03:40 AM : Outperform Start Price: $102.31 NVS Score: +1.14

Barron's List World's Greatest CEOs 3/23/15 - Joseph Jimenez

Recs

0
Member Avatar oncqueen (69.72) Submitted: 8/30/2014 10:11:55 AM : Outperform Start Price: $90.78 NVS Score: +9.30

New blockbuster drug for heart failure in the works, with a 20% reduction in death vs standard rx, and a decrease in hospitalization. Buying it in the real world next market day. Dividend around 2.7%, too.

Recs

1
Member Avatar bricehobbs (< 20) Submitted: 5/14/2014 1:46:32 PM : Outperform Start Price: $87.39 NVS Score: +7.44

Dividend, M & A activity, and pipeline.

Recs

1
Member Avatar fischdoctor (68.29) Submitted: 10/28/2013 8:22:30 AM : Outperform Start Price: $75.64 NVS Score: +17.20

good solid company.

Recs

1
Member Avatar alexf (< 20) Submitted: 8/29/2013 10:36:41 AM : Outperform Start Price: $69.33 NVS Score: +21.54

Good mix of products. Good management.

Recs

1
Member Avatar wilkeh (54.61) Submitted: 6/6/2013 10:15:14 AM : Outperform Start Price: $67.68 NVS Score: +22.71

diversified healthcare company will become the largest healthcare (pharma) company in the world in terms of revenue

Recs

0
Member Avatar kbelboe2 (36.22) Submitted: 7/13/2012 11:26:25 PM : Outperform Start Price: $51.66 NVS Score: +45.00

Another Euro drug manufacturer that now does generic stuff. Cheap and about to go higher.

Recs

0
Member Avatar pphamelin (74.81) Submitted: 6/26/2012 2:30:36 PM : Outperform Start Price: $50.46 NVS Score: +46.07

lack of patent protection overhyped

Recs

0
Member Avatar allegra (56.93) Submitted: 3/12/2012 2:07:13 PM : Outperform Start Price: $50.01 NVS Score: +53.41

pharmy and generic pipeline, biotech, plus optical

Recs

0
Member Avatar renoryan100 (57.08) Submitted: 2/29/2012 10:43:28 AM : Outperform Start Price: $50.64 NVS Score: +51.02

Dividend Monk

Recs

1
Member Avatar Raufus (< 20) Submitted: 2/26/2012 10:58:52 AM : Outperform Start Price: $50.87 NVS Score: +48.80

Novartis is the world's third largest pharmaceutical company with blockbuster products such as Glivec/Tasigna (cancer) and Gilenya (multiple sclerosis). PE at 9.6 and a net dividend yield of 4.8%. The market will reflect that.

Recs

1
Member Avatar Dan22italy (29.10) Submitted: 12/19/2011 1:00:13 AM : Outperform Start Price: $50.16 NVS Score: +33.98

one of best pharma, good dividend

Recs

0
Member Avatar starbucks4ever (98.23) Submitted: 11/18/2011 2:07:58 AM : Outperform Start Price: $49.24 NVS Score: +38.42

A reasonably safe bet. The management is finished destroying value through acquisitions: the last cash that remained to be squandered has been squandered last year, and during a debt crisis nobody will lend them money for the next purchase. That leaves us with a low PE, and with speculators assuming (mistakenly) that with no more empire building the "E" will finally accrue to them. This illusion will put a floor under the price, especially when the "E" is stable and speculators are desperately looking for stability.

Recs

0
Member Avatar MojoJoe (79.60) Submitted: 9/21/2011 11:34:38 AM : Outperform Start Price: $49.70 NVS Score: +32.58

Excellent company, great dividend analysis.

Recs

0
Member Avatar clayman14 (< 20) Submitted: 9/15/2011 4:30:29 PM : Outperform Start Price: $49.93 NVS Score: +33.80

Swiss Compant + Decent Yield + Pharma

Recs

0
Member Avatar beadnell (90.25) Submitted: 8/4/2011 6:17:09 AM : Outperform Start Price: $52.73 NVS Score: +27.18

It is a good day to buy European stocks (even cheaper than when I bought it.)

Recs

0
Member Avatar Jamanji (84.06) Submitted: 7/8/2011 10:36:44 AM : Outperform Start Price: $55.61 NVS Score: +28.87

Barrons 7-4-11

Recs

0
Member Avatar utri (< 20) Submitted: 7/1/2011 11:44:37 AM : Outperform Start Price: $54.31 NVS Score: +32.54

Has exposure to both patented and generic medicine.
Good balance sheet.
Should move up after Alcon acquisition is complete.

Featured Broker Partners


Advertisement